Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Traws Pharma, Inc. clinical trials
Also known as Onconova Therapeutics.
The registry lists 35 studies whose lead sponsor is Traws Pharma, Inc.. 5 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 3, 2026.
Keep track of what changes. Save the Traws Pharma, Inc. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Traws Pharma, Inc..
- Traws Pharma, Inc.35 studiesSame company
Something wrong?
Focus areas
Conditions Traws Pharma, Inc. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 35 of 35.
- Study of TRX-100 Evaluating the Safety, Pharmacokinetics, and Food Effect in Healthy VolunteersRecruitingNCT07526506Phase 1
- Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge ModelNot yet recruitingNCT07503405Phase 2
- Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19RecruitingNCT07157007Phase 2
- Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic MalignanciesRecruitingNCT05705505Phase 1/2
- Study of ON 123300 in Patients With Advanced CancerRecruitingNCT04739293Phase 1
- This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate InfluenzaActive, not recruitingNCT07371650Phase 2
- Evaluation Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of 83-0060 in Healthy VolunteersCompletedNCT06402136Phase 1
- A Clinical Study Aiming to Assess Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TRX-100 in Healthy VolunteersCompletedNCT06757738Phase 1
- Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMATerminatedNCT02562443Phase 3
- Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid TumorsTerminatedNCT02168725Phase 1
- Oral Rigosertib in Low Risk MDS Patients Refractory to ESAsCompletedNCT01904682Phase 2
- Phase II Part 2 Expansion of Oral Rigosertib in Combination With AzacitidineCompletedNCT01926587Phase 1/2
- Three Dosing Schedules of Oral Rigosertib in MDS PatientsWithdrawnNCT02075034Phase 1
- Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess BlastsCompletedNCT01241500Phase 3
- Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or DecitabineCompletedNCT01928537Phase 3
- Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)CompletedNCT00854646Phase 1
- Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer PatientsCompletedNCT00856791Phase 2
- Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic SyndromeCompletedNCT01584531Phase 2
- Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)CompletedNCT01167166Phase 1/2
- Oral Rigosertib for Squamous Cell CarcinomaCompletedNCT01807546Phase 2
- Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High RiskCompletedNCT00906334Phase 2
- Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AMLCompletedNCT00854945Phase 1/2
- Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid TumorsCompletedNCT01125891Phase 1
- Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck CancerCompletedNCT02107235Phase 1
- Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced CancerCompletedNCT01538563Phase 1
- Metabolism and Excretion of [14C]-Rigosertib After Infusion to VolunteersCompletedNCT02030639Phase 1
- Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic SyndromeCompletedNCT01048619Phase 1
- Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid TumorsCompletedNCT01168011Phase 1
- Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With HepatomaCompletedNCT00861783Phase 1
- Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid TumorsCompletedNCT01165905Phase 1
- Safety Study of ON 01910.Na in Combination With Irinotecan or OxaliplatinCompletedNCT00861328Phase 1
- Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)WithdrawnNCT00867061Phase 1/2
- Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced CancerCompletedNCT01538537Phase 1
- Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic CancerCompletedNCT01360853Phase 3
- Safety Study of ON 013105 in Lymphoma and Acute Lymphoid LeukemiaTerminatedNCT01049113Phase 1